Jeff Aronin, Paragon Biosciences CEO
Drug R&D hurdles hamper another biotech as a Jeff Aronin upstart shuts down
It’d be hard to quantify how many biotechs have quietly flown under the radar as “stealth” upstarts and then never emerged publicly because of data, financials or other reasons — unless every whisper from the grapevine makes it to your ears.
But many biotechs do announce themselves eventually, which means if the drug R&D hunt comes to an end — as happens so often in the grueling biopharma industry — then it’s more prone to become publicly known.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
